Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9576643 | 0.87 | PER2 (0.31) | — | |
| SCHEMBL16472471 | 0.78 | POLB (0.32) | — | |
| SCHEMBL24952511 | 0.77 | CHRM2 (0.32) | PIK3CD | |
| SCHEMBL9966010 | 0.72 | CHRM2 (0.43) | — | |
| SCHEMBL14681912 | 0.70 | HRH3 (0.31) | — | |
| SCHEMBL22200113 | 0.70 | GRIN2D (0.33) | — | |
| SCHEMBL11930037 | 0.70 | GRM5 (0.34) | — | |
| SCHEMBL18096285 | 0.70 | CACNA1H (0.33) | — | |
| SCHEMBL9963243 | 0.69 | CYP2D6 (0.36) | PIK3CD | |
| SCHEMBL16625642 | 0.69 | OPRM1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | ARTUS THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | ARTUS THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230193231-A1 | ENGINEERED GENE-EDITING PROTEINS | FACTOR BIOSCIENCE INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230193231-A1 | ENGINEERED GENE-EDITING PROTEINS | FACTOR BIOSCIENCE INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-01-26 | — | — | US | disclosed |
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
| CN-102167854-B | Conjugated diene series polymer rubber and conjugated diene series polymer rubber composition | SUMITOMO CO LTD | 2015-07-08 | — | — | CN | disclosed |
| US-20140315895-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140206811-A1 | CONJUGATED DIENE POLYMER RUBBER, AND CONJUGATED DIENE POLYMER RUBBER COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-07-24 | — | — | US | disclosed |
| US-20140011796-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8569341-B2 | Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110237737-A1 | CONJUGATED DIENE POLYMER RUBBER, AND CONJUGATED DIENE POLYMER RUBBER COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-09-29 | — | — | US | disclosed |
| US-5239003-A | PROCESS FOR PREPARATION OF STYRENE RESIN COMPOSITION AND STYRENE RESIN COMPOSITION | NIPPON ZEON CO., LTD. (JP) | 1993-08-24 | — | — | US | disclosed |
| US-5155161-A | Living polymer modified by lactam, urea, amino ketone or aldehyde or thio analogs, followed by hydrolysis | NIPPON ZEON CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0488346-A1 | Process for preparation of styrene resin composition and styrene resin composition | NIPPON ZEON CO., LTD. (JP) | 1992-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | CRBN, STUB1, ADRM1 | PIK3CD 2489/4885RAB9A 3009/4885SMN1; SMN2 1473/4885 |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | PIK3CD 1287/4885RAB9A 1177/4885SMN1; SMN2 4326/4885 |
| US-20140011796-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | PIK3CD 493/4885RAB9A 2963/4885SMN1; SMN2 3370/4885 |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | PIK3CD 421/4885RAB9A 3619/4885SMN1; SMN2 3854/4885 |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | PIK3CD 493/4885RAB9A 2963/4885SMN1; SMN2 3370/4885 |
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | PIK3CD 493/4885RAB9A 2963/4885SMN1; SMN2 3370/4885 |
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | LIPG, FABP2, EPCAM | PIK3CD 1756/4885RAB9A 2162/4885SMN1; SMN2 4232/4885 |
| US-20140315895-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | PIK3CD 493/4885RAB9A 2963/4885SMN1; SMN2 3370/4885 |
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | PIK3CD 3727/4885RAB9A 435/4885SMN1; SMN2 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.